SCHEMBL17059906

SCHEMBL17059906

Cc1cccc2c1N(C)c1cc(N[C@H]3CC[C@H](O)CC3)ncc1N(C)C2=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 10/20 0.74
▸ MAPK7 Q13164 9/20 0.74
▸ BRD2 P25440 1/20 0.54
▸ EP300 Q09472 1/20 0.54
▸ BRD3 Q15059 1/20 0.54
▸ BRDT Q58F21 1/20 0.54
▸ CREBBP Q92793 1/20 0.54
▸ CCNT1 O60563 6/20 0.42
▸ RIPK2 O43353 1/20 0.41
▸ DCLK1 O15075 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PIK3CD O00329 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ PIK3C2G O75747 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18370037 0.89 BRD4 (0.73) BRD4MAPK7BRD2EP300BRD3
SCHEMBL17059942 0.89 BRD4 (0.73) BRD4MAPK7BRD2EP300BRD3
SCHEMBL17059962 0.87 MAPK7 (0.71) BRD4MAPK7BRD2EP300BRD3
SCHEMBL17059803 0.85 MAPK7 (1.00) BRD4MAPK7BRD2EP300BRD3
SCHEMBL18369858 0.85 MAPK7 (1.00) BRD4MAPK7BRD2EP300BRD3
SCHEMBL17059837 0.85 MAPK7 (1.00) BRD4MAPK7BRD2EP300BRD3
SCHEMBL18370032 0.82 MAPK7 (0.84) BRD4MAPK7BRD2EP300BRD3
SCHEMBL17059964 0.80 BRD4 (0.72) BRD4MAPK7BRD2EP300BRD3
SCHEMBL17059920 0.80 MAPK7 (0.88) BRD4MAPK7BRD2EP300BRD3
SCHEMBL18370039 0.80 MAPK7 (0.88) BRD4MAPK7BRD2EP300BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed
WO-2015129927-A1 HETEROCYCLIC COMPOUNDS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008888-A1 HETEROCYCLIC COMPOUNDS BET1, EP300, RBBP5 BRD4 4/4885MAPK7 58/4885BRD2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback